2024
Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings?
Palacios C, Chowdhary V, Hao R, Danve A, Malinis M. Is yearly interferon gamma release assay latent tuberculosis infection screening warranted among patients with rheumatological diseases on disease-modifying drugs in non-endemic settings? PLOS ONE 2024, 19: e0306337. PMID: 38959249, PMCID: PMC11221665, DOI: 10.1371/journal.pone.0306337.Peer-Reviewed Original ResearchConceptsInterferon-gamma release assayDisease-modifying antirheumatic drugsInterferon-gamma release assay testLatent tuberculosis infectionNon-endemic settingsRheumatologic diseasesRisk factorsPositive interferon-gamma release assayLatent tuberculosis infection screeningLatent tuberculosis infection diagnosisPositive IGRA testMonths of rifampinLow-risk patientsRetrospective chart reviewTNF-alpha inhibitorsTB risk factorsTargeted LTBI screeningOutpatient rheumatology clinicDisease-modifying drugsIGRA testPatient demographicsAdult patientsChart reviewAntirheumatic drugsNon-endemic areas
2021
Update on gout management: what is old and what is new
Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Current Opinion In Rheumatology 2021, 34: 118-124. PMID: 34907116, PMCID: PMC8799507, DOI: 10.1097/bor.0000000000000861.Peer-Reviewed Original ResearchConceptsUrate-lowering therapyRisk factorsAdjunctive management strategiesUrate-lowering efficacyChronic kidney diseaseUse of allopurinolAllopurinol hypersensitivity syndromeManagement of hyperuricemiaCrystal-Associated Disease NetworkPopulation attributable riskEvidence-based recommendationsComprehensive evidence-based recommendationsNew drug therapiesGout guidelinesCause mortalityHypersensitivity syndromeCardiovascular riskGout flaresGout managementKidney diseaseDrug therapyFlare managementAttributable riskDietary factorsSerum urate